Last updated: March 16, 2022
Sponsor: Poitiers University Hospital
Overall Status: Trial Not Available
Phase
3
Condition
Fever
Neutropenia
Treatment
N/AClinical Study ID
NCT04698057
ACACIA
Ages 18-110 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patient ≥ 18 years old
- Treated for a solid cancer or a hematological malignancy
- Presented with low-risk* febrile neutropenia due to chemotherapy with an expectedduration of neutropenia ≤ 7 days
- Neutropenia is defined by an absolute neutrophil count ≤ 500/mm3.
- Fever is defined by temperature ≥ 38.3° or ≥ 38° twice during a 1-hour interval.
- Signing informed consent *Low risk is defined by MASCC score ≥ 21
Exclusion
Exclusion Criteria:
- Hypersensitivity to the active substances: amoxicillin-clavulanic, ciprofloxacin,penicillins, to other quinolones or to one of the excipient
- History of severe immediate hypersensitivity reaction to another beta-lactam
- History of jaunditis/hepatic impairment related to amoxicillin/clavulanic
- Concomitant administration of ciprofloxacin and tizanidine.
- Clinical signs of focal infection including history of untreated dental abscess.
- Signs of sepsis or organ failure.
- Severe immune deficiency other than the current cancer, except controlled-HIVinfection
- Gastrointestinal symptoms requiring intravenous treatment (mucositis, vomiting, severediarrhea...).
- Known aminotransferase serum levels > 5 x normal values.
- Known renal insufficiency defined as creatinine clearance of < 30 mL/min (MDRD).
- Antibiotherapy within 24h before enrollment. Prophylactic use of amoxicillin is anexclusion criterium whereas prophylactic use of trimethoprim-sulfamethoxazole (cotrimoxazole) and penicillin G (Oracilline®) are not and will be considered in theanalysis.
- History of infection or colonization due to bacteria resistant to experimental drugsin the previous year
- Can be enrolled in the study only once.
- Patients not benefiting from a Social Security scheme or not benefiting from itthrough a third party.
- Persons benefiting from enhanced protection, namely minors, persons deprived of theirliberty by a judicial or administrative decision, persons staying in a health orsocial institution, adults under legal protection, and finally patients in emergencies
- Pregnant or breastfeeding women, women at age to procreate and not using effectivecontraception (either hormonal / mechanical : oral, injection, subcutaneous,implantable, intrauterine device, or surgical : tubal ligation, hysterectomy, totalovariectomy).
Study Design
Study Start date:
March 01, 2022
Estimated Completion Date:
June 01, 2025